Press

Beckley Psytech completes oversubscribed $80m fundraise to develop portfolio of psychedelic medicine breakthroughs

Aug 17 • 5 min read

Quick Take: Privately held company Beckley Psytech has completed a Series B financing, raising $80m from VC investors. Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC)…

Ketamine One Subsidiary KGK Science Secures Multiple New Contracts

Aug 16 • 4 min read

Quick Take: KGK, a subsidiary of Ketamine One, is negotiating to secure over $2.3M of net new revenue. KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization, KGK…

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

Aug 16 • 7 min read

Quick Take: atai has released their Q2 financial report and business update. This includes details on their IPO, a $20M upfront payment from a collaboration with Otsuka, and $453.6M investment to advance their current programs and explore new ones. atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment…

Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy

Aug 13 • 4 min read

Quick Take: Core One Labs’ wholly owned subsidiaries Rejuva Mental Health Clinic and Bluejay Mental Health Group have partnered to assist their patient with submitting an application for an exemption under the Controlled Substances Act. Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in…

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th

Aug 12 • 2 min read

Quick Take: Awakn announces that it is qualified to begin trading on the OTCQB Venture Market under the the ticker “AWKNF” starting today. Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441